ChemoCentryx to Present at the 9th Annual SVB Leerink Global Healthcare Conference
19 févr. 2020 08h30 HE
|
ChemoCentryx, Inc.
MOUNTAIN VIEW, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the...
ChemoCentryx Announces Credit Facility of Up to $100 Million with Hercules Capital
09 janv. 2020 08h30 HE
|
ChemoCentryx, Inc.
MOUNTAIN VIEW, Calif., Jan. 09, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ: CCXI) today announced that the Company has secured a credit facility of up to $100 million provided by Hercules...
ChemoCentryx to Present at the 38th Annual JP Morgan Healthcare Conference
08 janv. 2020 08h30 HE
|
ChemoCentryx, Inc.
MOUNTAIN VIEW, Calif., Jan. 08, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the...
ChemoCentryx to Present at the 31st Annual Piper Jaffray Healthcare Conference
26 nov. 2019 08h30 HE
|
ChemoCentryx, Inc.
MOUNTAIN VIEW, Calif., Nov. 26, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the...
ChemoCentryx and VFMCRP Announce Positive Topline Data from Pivotal Phase III ADVOCATE Trial Demonstrating Avacopan’s Superiority Over Standard of Care in ANCA-Associated Vasculitis
25 nov. 2019 16h05 HE
|
ChemoCentryx, Inc.
-- Achieved both primary endpoints of clinical remission at weeks 26 and 52 with statistical superiority of avacopan over standard of care (SOC) at 52 weeks -- -- Significantly reduced...
Presentations at ASN Kidney Week 2019 Highlight Breadth of ChemoCentryx Platform in Treatment of Complement 3 Glomerulopathy (C3G) and Focal Segmental Glomerulosclerosis (FSGS)
05 nov. 2019 08h30 HE
|
ChemoCentryx, Inc.
-- Highlights Study Design, Outcome Measures, and Baseline Patient Data in the Ongoing Avacopan ACCOLADE Phase II Trial in C3G -- Reinforces Therapeutic Potential of Chemokine Receptor 2 (CCR2)...
ChemoCentryx Reports Third Quarter 2019 Financial Results and Recent Highlights
04 nov. 2019 16h05 HE
|
ChemoCentryx, Inc.
-- Topline data from pivotal ADVOCATE Phase III trial of C5a receptor inhibitor avacopan in ANCA vasculitis expected mid-to-late fourth quarter -- -- Awarded $1 million grant from the U.S. Food and...
ChemoCentryx to Hold Third Quarter 2019 Financial Results Conference Call on Monday, November 4, 2019
28 oct. 2019 08h30 HE
|
ChemoCentryx, Inc.
MOUNTAIN VIEW, Calif., Oct. 28, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's third quarter 2019 financial results will be released after market...
ChemoCentryx to Host R&D Day on October 1, 2019
24 sept. 2019 08h30 HE
|
ChemoCentryx, Inc.
MOUNTAIN VIEW, Calif., Sept. 24, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that it will host an R&D Day on Tuesday, October 1, 2019 beginning at 12:00 p.m. ET...
ChemoCentryx to Present at Two Upcoming Investor Conferences
29 août 2019 08h30 HE
|
ChemoCentryx, Inc.
MOUNTAIN VIEW, Calif., Aug. 29, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two...